Aims and objectives of workstreams
Read more
STEP Database
Safety and Toxicity of Excipients for Paediatrics
Read more
Become a member and support us.
Read more
News & Events

14th EuPFI Conference 2022   Rome, Italy

Read More

About EuPFI

European Paediatric Formulation Initiative (EuPFI) is a consortium working in a pre-competitive way on paediatric drug formulations. Members are from academia, hospital pharmacies, pharmaceutical industry (Innovators, Generics,Contract Research Organizations (CRO), Specials and Excipient Manufacturers) with European Medicine Agency (EMA) as an observer. It aims to expedite the development of better and safer medicines for children by identifying and scoping issues and challenges in paediatric formulation development. It brings together the voluntary, academic, pharmaceutical industry, hospitals and regulatory agency in order to tackle the development of age appropriate formulation for paediatrics. It provides funding, expertise and resources to support the solutions to the problems and new technologies emerging from academic research.

To promote and facilitate preparation of better & safe medicines for children through:

Sharing expertise and interactive discussion between industry, academia, clinical and regulatory professionals,
Information dissemination,
Raising awareness (publications, conferences etc),
linking and networking.

Identify the issues and challenges associated with development of paediatric formulation and consider ways towards better medications and clinically relevant dosage forms for children.
Promote early pharmaceutical consideration for development of paediatric medicines.
Identify potential information, knowledge, know-how gaps in the paediatric formulation development.
Improve the availability of information of paediatric formulations.

Quick Facts
Non profit organisation.
Established in London in 2007.
Members from industry, academia, hospital and regulatory agencies dedicated to fulfilling its mission.
Membership open to anyone interested in paediatric
formulation development.
5 Workstreams.
Annual Conferences.

Meet The Team

Our Structure and Operation

Networks & Collaborations

Global Research in Paediatrics – Network of Excellence (GRiP)

Global Research in Paediatrics (GRIP) is a European Commission funded program which aims to stimulate and facilitate the development and safe use of medicine in children.

United States Paediatric Formulation initiative (USPFI)

EuPFI and USPFI are working together on the common project to build a database gathering safety data on excipients used in paediatric formulations.

The International Consortium for Innovation and Quality in Pharmaceutical Development (IQ)

The International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) is a technically-focused organization of pharmaceutical and biotechnology companies with a mission of advancing science-based and scientifically-driven standards and regulations for pharmaceutical and biotechnology products worldwide. In January 2014 IQ joined the European Pediatric Formulation Initiative (EuPFI) to further efforts to promote global alignment on pediatric product development. EuPFI is a consortium that has been instrumental in driving science and science-based standardization for pediatric formulation development. Membership in EuPFI allows IQ and EuPFI to join forces in addressing a topic with public health significance.

European Study of Neonatal Excipient Exposure (ESNEE)

Excipients are used to facilitate the manufacturing of dosage forms and maintain the stability of medicines in the face of chemical and microbial challenges. The lack of neonatal safety information exposes these patients to the risk of specific adverse reactions unexpected from adult experience.

The ESNEE project, "Strategy for the extensive review of the literature on excipient toxicities" aimed to develop and validate a systematic and standardised search strategy for collecting relevant information about excipients.

Technology Strategy Board (TSB)

EuPFI in collaboration with its network of partners secured a £660,000 grant from the Technology Strategy Board, the UK’s innovation agency, towards a £1 million project aimed at accelerating paediatric formulation development through smart design and predictive science.

The consortium aimed to address the need for improved speed, cost and quality of paediatric formulation by drawing on the combined expertise of its members. The goal was to deliver a novel, commercially available, regulatory-approved platform to identify the most appropriate delivery strategy for paediatric medicines.

European Medicine Agency (EMA)

The EMA acts as a continuous observer of EuPFI's research activities.

The European Paediatric Translational Research Infrastructure (EPTRI)

The strategic objective of EPTRI WP 8 is to create a coordinated EU paediatric formulation platform, as part of a Paediatric Infrastructure, bringing together the major European research groups/networks (such as European Pediatric Formulation Initiatives (EuPFI) to join forces and ultimately, to respond in a concerted way to scientific questions in order to tackle the challenges in developing paediatric formulations and to increase its visibility and impact. The EuPFI has collaborated with EPTRI and working on adminsitration survey as part of this workpackage


Print Friendly, PDF & Email